Evaluation of Urea-Based Inhibitors of the Dopamine Transporter Using the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis

The dopaminergic system is involved in the regulation of immune responses in various homeostatic and disease conditions. For conditions such as Parkinson’s disease and multiple sclerosis (MS), pharmacological modulation of dopamine (DA) system activity is thought to have therapeutic relevance, provi...

Full description

Saved in:
Bibliographic Details
Published in:ACS chemical neuroscience 2022-01, Vol.13 (2), p.217-228
Main Authors: Ashraf-Uz-Zaman, Md, Ji, Guangchen, Tidwell, Dalton, Yin, Linda, Thakolwiboon, Smathorn, Pan, Jie, Junell, Riley, Griffin, Zach, Shahi, Sadisna, Barthels, Derek, Sajib, Md Sanaullah, Trippier, Paul C, Mikelis, Constantinos M, Das, Hiranmoy, Avila, Mirla, Neugebauer, Volker, German, Nadezhda A
Format: Article
Language:English
Subjects:
Animals
Dopamine Plasma Membrane Transport Proteins
Encephalomyelitis, Autoimmune, Experimental - drug therapy
Multiple Sclerosis - drug therapy
Neuroinflammatory Diseases
Urea
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The dopaminergic system is involved in the regulation of immune responses in various homeostatic and disease conditions. For conditions such as Parkinson’s disease and multiple sclerosis (MS), pharmacological modulation of dopamine (DA) system activity is thought to have therapeutic relevance, providing the basis for using dopaminergic agents as a treatment of relevant states. In particular, it was proposed that restoration of DA levels may inhibit neuroinflammation. We have recently reported a new class of dopamine transporter (DAT) inhibitors with high selectivity to the DAT over other G-protein coupled receptors tested. Here, we continue their evaluation as monoamine transporter inhibitors. Furthermore, we show that the urea-like DAT inhibitor (compound 5) has statistically significant anti-inflammatory effects and attenuates motor deficits and pain behaviors in the experimental autoimmune encephalomyelitis model mimicking clinical signs of MS. To the best of our knowledge, this is the first study reporting the beneficial effects of DAT inhibitor-based treatment in animals with induced autoimmune encephalomyelitis, and the observed results provide additional support to the model of DA-related neuroinflammation.
ISSN:1948-7193
1948-7193
DOI:10.1021/acschemneuro.1c00647